In traditional clinical research, “Explanatory Trials” are the gold standard. They occur in highly controlled environments with strict inclusion criteria to answer a specific question: Can this intervention work? However, once a drug or device enters the real world, the “perfect patient” disappears. This is where Pragmatic Clinical Trials (PCTs) become essential.

Pragmatic trials are designed to show how an intervention works in real-life healthcare settings. They bridge the gap between scientific theory and clinical practice, providing the data that payers, providers, and patients actually need to make informed decisions.

Explanatory vs. Pragmatic: Understanding the Spectrum

The difference between these two approaches is often visualized using the PRECIS-2 tool, which evaluates trials based on nine domains, including participant eligibility, recruitment, and setting.

• Explanatory Trials: Aim for internal validity. They use “clean” populations, excluding patients with comorbidities or those taking multiple medications.
• Pragmatic Trials: Aim for external validity (generalizability). They include a diverse range of patients, use local clinical staff to deliver the intervention, and measure outcomes that matter in a real-world clinic, such as quality of life or long-term adherence.

Why the FDA and Payers are Moving Toward “Pragmatic”

There is a growing “evidence gap” in healthcare. Regulators and insurance providers are increasingly skeptical of data that only applies to a tiny, “perfect” slice of the population.

The shift toward pragmatic research is driven by:

1. Real-World Evidence (RWE): The 21st Century Cures Act has pushed the FDA to integrate RWE into regulatory decision-making. Pragmatic trials are a primary source of this data.
2. Comparative Effectiveness: Payers want to know not just if a drug works, but if it works better than the current standard of care in a typical hospital setting.
3. Cost-Efficiency: Because PCTs often use existing electronic health records (EHRs) and integrated clinical workflows, they can be significantly cheaper and faster than traditional Phase III trials.

Key Challenges in Pragmatic Design

While the benefits are clear, “going pragmatic” introduces unique complexities that researchers must navigate:

1. Informed Consent in the Flow of Care In a traditional trial, consent is a lengthy, separate process. In a pragmatic trial, researchers must find ways to obtain consent without disrupting the patient’s normal clinical visit—sometimes using “short-form” or electronic consent models.

2. Data Integrity and “Messy” Data When you move out of a controlled research center and into a community hospital, the data gets “noisy.” Relying on EHRs means dealing with missing data, varying coding standards, and inconsistent follow-up.

3. Blinding and Randomization It is often difficult to “blind” a pragmatic trial when the intervention involves a change in clinical procedure or a visible medical device. This requires creative statistical approaches to minimize bias.

The Impact on Healthcare Policy

Pragmatic trials don’t just result in a publication; they result in a change in policy. By demonstrating how a treatment performs in the “chaos” of daily practice, these trials provide the final piece of the puzzle for market access and widespread clinical adoption.

How do you choose the right “Pragmatic” vs “Explanatory” balance for your specific product? What are the latest FDA insights on using EHR data for primary endpoints?

Move from Theory to Real-World Practice

Mastering the pragmatic approach is no longer optional for clinical strategists—it is a competitive necessity. To help you navigate this transition, we are hosting a strategic webinar: “Pragmatic Trials: Bridging Theory to Practice in Healthcare Research.”

Join us to explore the PRECIS-2 framework, learn strategies for capturing high-quality data in “messy” environments, and see how to design trials that satisfy both regulators and payers.

Register for the Webinar: Pragmatic Trials – Theory to Practice